Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Lorbrena (lorlatinib)
pCPA File Number:
21182
Negotiation Status:
Negotiations were not pursued
Indication(s):
Non-Small Cell Lung Cancer (ALK+)
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
pCODR 10183
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
2020-04-21